MB21D2
Overview
MB21D2 (MB21 Domain Containing 2), previously known as C3orf59, is a gene of emerging interest in lung cancer genomics. It was identified in the TCGA pan-lung cancer analysis as harboring a recurrent missense mutation (p.Q311E) with predicted neoepitope properties, marking it as a novel candidate immunogenic driver in non-small cell lung cancer.
Alterations observed in the corpus
- MB21D2 harbors a recurrent p.Q311E missense mutation with predicted neoepitope properties in pan-lung cancer TCGA analysis (n=1144); not previously implicated in lung cancer PMID:27158780
Cancer types (linked)
- Lung adenocarcinoma / lung squamous cell carcinoma: recurrent p.Q311E mutation with predicted immunogenic neoepitope PMID:27158780
Co-occurrence and mutual exclusivity
- No co-occurrence or mutual exclusivity patterns reported in the corpus.
Therapeutic relevance
- The predicted neoepitope at MB21D2 p.Q311E suggests potential relevance for neoantigen-based immunotherapy approaches in lung cancer PMID:27158780
Open questions
- The functional consequence of MB21D2 p.Q311E and whether this mutation drives tumorigenesis or merely serves as an immunogenic marker remains unresolved PMID:27158780
Sources
This page was processed by entity-page-writer on 2026-05-15.